GLP-1 drugs, such as Wegovy and Ozempic, are gaining popularity in the US and Europe for their appetite-suppressing ...

A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal ...

Amylyx Pharmaceuticals has named Dan Monahan as chief commercial officer, positioning an exec who led the U.S.

Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug ...

Novo Nordisk filed another petition with the FDA seeking to block compounding pharmacies from making versions of one of its GLP-1 drugs ...

For this review, the authors searched for randomized controlled trials published in MEDLINE, Embase, and Cochrane CENTRAL ...

Purchases of calorie-dense, processed items such as chips, baked goods and cookies were most affected, according to findings ...

Achieving and maintaining a healthy weight is beneficial for a number of reasons. A healthy weight lowers a person's chance ...

The surging popularity of GLP-1 drugs is beginning to obscure the health consequences if people stop taking them, physicians ...

Not long after the FDA wrapped its preliminary investigation of GLP-1 receptor agonists and suicidal thoughts or actions, the ...

GLP-1 weight-loss drugs are cutting calories… and grocery bills, according to a new study from Cornell and Numerator.

Experts say patients should adjust dosage, try prescribed and over-the-counter drugs to help with symptom management and ...